ClinicalTrials.gg
Active, not recruitingNCT04241341Updated Feb 27, 2026

Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection

A Phase 3 interventional study of Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction in Breast Cancer Lymphedema, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Breast Cancer Lymphedema with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Breast Cancer Lymphedema · United States.

Enrollment
2nd of 12
180 · median 45
Started
2020
with 3 others
Phase 3
Only one
of the 15
Registered
2nd of 15
by date
Lead sponsor
1 of 15
Memorial Sloan Kettering Cancer Center

Among the 15 studies in Breast Cancer Lymphedema with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2020, is the only one in phase 3, and was the 2nd registered.

Breast Cancer Lymphedema

124 studies on the registry are indexed under Breast Cancer Lymphedema; 39 are open to participants now.

Browse Breast Cancer Lymphedema studies →

Open to participants now

8 of the 15 studies in Breast Cancer Lymphedema with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Breast Cancer Lymphedema studies recruiting now, 8 (33%) set no upper age limit and 9 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Breast Cancer Lymphedema with a site in United States, or all of them as a file.
02

Study summary

The researchers are doing this study to see if having immediate lymphatic reconstruction after axillary lymph node dissection (ALND) can decrease the development of lymphedema, a side effect of ALND. Other purposes of the study include:

Comparing the approach of immediate lymphatic reconstruction after ALND with the approach of ALND alone Looking at whether having immediate lymphatic reconstruction after ALND improves a person's quality of life Seeing if adding standard of care radiation therapy to either study approach (immediate lymphatic reconstruction after ALND or ALND alone) has an effect on development of lymphedema

03

Conditions studied

  • Breast Cancer Lymphedema

Keywords

  • Axillary Lymph Node Dissection
  • Lymphatic Reconstruction
  • 20-021
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female breast cancer patients 18-75 years of age
  • Patients consenting for unilateral ALND (prior history of SLNBx allowed if \<6 months from consent) OR patients consenting for unilateral SLNBx with possible ALND, with a clinically or radiographically positive lymph node OR a high likelihood of ALND per the Breast Surgeon
  • Identification of at least one transected lymphatic channel and at least one vein to be used for bypass at the time of ALND during surgery

Exclusion criteria

Exclusion Criteria:

  • Male breast cancer patients
  • Non-English speaking participants
  • Female breast cancer patients with axillary recurrence
  • Female breast cancer patients who have a history of ALND
  • Female patients requiring bilateral ALND for the treatment of their breast cancer
  • Female breast patients treated with SLNBx only
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    axillary lymph node dissection with ILR

    Procedure: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction · Other: quality-of-life questionnaires · Other: measured by arm volume

  • Active comparator
    axillary lymph node dissection (ALND) without ILR

    Procedure: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction · Other: quality-of-life questionnaires · Other: measured by arm volume

Interventions

  • ProcedureAxillary Lymph Node Dissection with Immediate Lymphatic Reconstruction

    Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction

  • ProcedureAxillary Lymph Node Dissection without Immediate Lymphatic Reconstruction

    Current standard treatment at Memorial Sloan Kettering \[MSK\]).

  • Otherquality-of-life questionnaires

    Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.

  • Othermeasured by arm volume

    Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis

06

What researchers measure

Primary outcomes

  1. the number of patients that had a decrease incidence of lymphedema

    as measured by arm volume will be a ≥10% increase in arm volume

    Time frame: up to 2 years

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Jan 2027, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2020
First posted
Jan 27, 2020
StartActual
Jan 22, 2020
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04241341
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Jan 22, 2020
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Michelle Coriddi, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion